Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer

Table 4

Serum HA, SHAP-HA complex, MMP-2, MMP-9, TIMP-1, and UTI in relation to the expression of HAS1, HAS2, and HAS3 in patients with endometrial cancer.

	𝑛	Hyaluronan; (ng/mL)	SHAP-HA complex; (U/mL)	UTI; (μg/mL)	MMP-2; (ng/mL)	MMP-9; (ng/mL)	TIMP-1; (ng/mL)
HAS1 expression
Negative	21	298.22±154.04	1.168±0.917	2.390±2.047	719.10±207.79	504.76±205.00	183.38±67.60
Positive	29	418.93±268.23	4.833±3.403	10.345±19.119	692.97±164.84	904.14±617.70	253.07±111.36
		𝑃=0.0705	𝑃<0.0001	𝑃=0.0643	𝑃=0.6223	𝑃=0.0065	𝑃=0.0142
HAS2 expression
Negative	18	349.8±216.78	2.851±2.624	3.756±5.973	734.22±212.04	787.28±525.09	244.44±120.89
Positive	32	378.6±244.82	3.543±3.511	8.831±18.127	686.91±164.86	707.78±525.09	212.19±87.5
		𝑃=0.6796	𝑃=0.4694	𝑃=0.2563	𝑃=0.3845	𝑃=0.6118	𝑃=0.2819
HAS3 expression
Negative	21	344.49±242.18	3.950±3.684	8.010±16.122	744.57±157.21	798.76±625.46	252.67±122.38
Positive	29	385.43±229.38	2.819±2.778	6.276±14.460	674.52±196.27	691.24±443.27	202.90±77.48
		𝑃=0.5061	𝑃=0.2226	𝑃=0.6919	𝑃=0.1832	𝑃=0.4798	𝑃=0.0848

Values are shown as mean ± SD.